Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a San Diego-based commercial mRNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. News about Arcturus often centers on clinical trial progress, regulatory interactions and collaboration updates linked to its LUNAR® lipid-mediated delivery and STARR® self-amplifying mRNA (sa-mRNA) platforms.
Investors following ARCT news can expect regular updates on the companys RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), including interim data from Phase 1 and Phase 2 studies, safety and tolerability findings, biomarker changes and plans for longer-duration or pivotal trials. Disclosures have highlighted programs such as ARCT-032, an inhaled mRNA therapy for CF, and ARCT-810, an mRNA therapeutic candidate for OTC deficiency.
Arcturus also issues frequent announcements related to its infectious disease vaccine portfolio. These include developments for KOSTAIVE®, described as the first approved self-amplifying mRNA COVID-19 vaccine, along with sa-mRNA influenza candidates like ARCT-2138 and pandemic influenza A H5N1 candidate ARCT-2304. News items may cover Phase 1 or Phase 3 data, immunogenicity and safety results, and regulatory submissions or approvals in collaboration with CSL Seqirus and partners such as Meiji Seika Pharma.
Additional ARCT headlines often involve financial results, cash runway commentary, cost management actions, investor conference participation and SEC filings that provide corporate updates. Stock Titans ARCT news page aggregates these company press releases, regulatory disclosures and related coverage so readers can track how Arcturus clinical, regulatory and partnership milestones may influence sentiment around ARCT stock over time.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the approval of stock options for 16 newly-hired employees, totaling 185,700 shares. The options, with an exercise price of $36.65 per share, are a part of the employment compensation package and will vest over four years. This move is in accordance with Nasdaq Rule 5635(c)(4) as an inducement for accepting employment. The stock options are contingent upon filing a Form S-8 Registration Statement, which has already been filed.
Arcturus Therapeutics Holdings announced the completion of enrollment for its ARCT-154 COVID-19 vaccine trial, involving over 17,000 participants, and plans to submit an Emergency Use Authorization (EUA) application with Vietnam's Ministry of Health. A Phase 3c sub-study is also underway, aiming for comparison with AstraZeneca's vaccine. Financial results for Q3 2021 show revenues of $2.4 million and a net loss of $54.1 million. Operating expenses have increased significantly, particularly in research and development, which totaled $45.4 million.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) will announce its third quarter financial results for the period ending September 30, 2021, post-market on November 8, 2021. A conference call is scheduled for 4:30 PM EST on the same day, allowing investors to engage directly with company leaders. The company, focused on mRNA medicines, has a diverse pipeline including vaccines for COVID-19 and influenza, along with treatments for rare diseases. Investors can access the call via a provided webcast link.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced the appointment of Dr. Nirdosh Jagota as Chief Regulatory Officer and Dr. Dushyant B. Varshney as Chief Technology Officer. Dr. Jagota brings over 30 years of regulatory experience, previously holding roles at Merck and Genentech. Dr. Varshney, with over 25 years in biotech, has a strong background in product lifecycles at organizations such as Kite Pharma and Pfizer. These additions aim to enhance Arcturus’ manufacturing capabilities and regulatory engagement as they advance their pipeline of RNA therapeutics and vaccines.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the approval of stock options for five new employees, totaling 57,200 shares, contingent upon filing a Form S-8 Registration Statement. The options have an exercise price of $46.98, based on the closing stock price on October 15, 2021. They come with a ten-year term and vest over four years. This inducement grant is part of each individual's compensation package and supports Arcturus' focus on developing mRNA medicines, including vaccines for infectious diseases and therapies for rare liver and respiratory diseases.
Arcturus Therapeutics has initiated the Phase 3b dosing of ARCT-154, a self-replicating RNA vaccine targeting the SARS-CoV-2 delta variant. This trial, approved by the Vietnam Ministry of Health, aims to enroll approximately 20,000 participants, with half receiving the vaccine. Following a review of safety data from 1,000 Phase 1/2/3a participants, the company is on track to file for Emergency Use Authorization (EUA) in December 2021. This advancement brings Arcturus closer to offering a potentially best-in-class vaccine option in Vietnam and beyond.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has met with Vietnam's President Nguyen Xuan Phuc and Vingroup's CEO Nguyen Viet Quang to discuss their recent collaboration for COVID-19 vaccine manufacturing. CEO Joseph Payne expressed optimism about expanding this collaboration, highlighting Vietnam's proactive public health strategy. This collaboration aims to support Vietnam's vaccination efforts against COVID-19 variants. Arcturus specializes in mRNA medicines and has a diverse pipeline of RNA therapeutics and vaccines.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has successfully completed the dosing of 100 participants in the Phase 1 trial for its ARCT-154 vaccine and has received approval to proceed to Phase 2 and Phase 3a. The Phase 2 trial will involve an additional 300 participants, while Phase 3a will assess safety and immunogenicity in 600 more. Phase 3b is set to begin with 20,000 participants in early October. Arcturus aims to file for Emergency Use Authorization in Vietnam by December, addressing the urgent need for effective vaccines against COVID-19 variants.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) will participate in Citi's 16th Annual BioPharma Virtual Conference 2021.
Founded in 2013 in San Diego, California, Arcturus is focused on clinical-stage messenger RNA medicines, particularly in infectious disease vaccines and rare liver and respiratory diseases. The company's advanced technologies include LUNAR® lipid-mediated delivery and STARR™ mRNA Technology. Arcturus has a diverse pipeline, including candidates for SARS-CoV-2, Influenza, and Ornithine Transcarbamylase Deficiency, among others.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announces its participation in several upcoming investor and scientific conferences, showcasing its advancements in mRNA medicines for infectious diseases and rare liver and respiratory conditions. Key events include presentations at the Wells Fargo Virtual Healthcare Conference on September 10, the H.C. Wainwright Global Investment Conference on September 13, and others through September 30. Investors can access links for conference details on Arcturus’ website.